SG11202112909SA - Method of providing safe administration of an anti-cd40 antibody - Google Patents
Method of providing safe administration of an anti-cd40 antibodyInfo
- Publication number
- SG11202112909SA SG11202112909SA SG11202112909SA SG11202112909SA SG11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- variable region
- chain variable
- seq
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853488P | 2019-05-28 | 2019-05-28 | |
| PCT/IB2020/055023 WO2020240434A1 (en) | 2019-05-28 | 2020-05-27 | Method of providing safe administration of an anti-cd40 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112909SA true SG11202112909SA (en) | 2021-12-30 |
Family
ID=70918772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112909SA SG11202112909SA (en) | 2019-05-28 | 2020-05-27 | Method of providing safe administration of an anti-cd40 antibody |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230174658A1 (https=) |
| EP (1) | EP3976651A1 (https=) |
| JP (2) | JP7755999B2 (https=) |
| KR (1) | KR20220012918A (https=) |
| CN (1) | CN113939535A (https=) |
| AU (1) | AU2020284706A1 (https=) |
| BR (1) | BR112021023906A2 (https=) |
| CA (1) | CA3142226A1 (https=) |
| IL (1) | IL288288A (https=) |
| MA (1) | MA56027A (https=) |
| MX (1) | MX2021014572A (https=) |
| SG (1) | SG11202112909SA (https=) |
| WO (1) | WO2020240434A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122355A2 (en) * | 2021-12-24 | 2023-06-29 | Sapience Therapeutics, Inc. | Methods of treating or preventing infusion-related reactions |
| TW202342057A (zh) * | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070003557A1 (en) * | 2005-04-21 | 2007-01-04 | Andres Forero | Method for treating cancer using premedication |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| CA2957146A1 (en) * | 2014-08-12 | 2016-02-18 | Alligator Bioscience Ab | Combination therapies with anti cd40 antibodies |
| WO2018160917A1 (en) | 2017-03-03 | 2018-09-07 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
-
2020
- 2020-05-27 AU AU2020284706A patent/AU2020284706A1/en active Pending
- 2020-05-27 EP EP20729226.9A patent/EP3976651A1/en active Pending
- 2020-05-27 CA CA3142226A patent/CA3142226A1/en active Pending
- 2020-05-27 CN CN202080039748.6A patent/CN113939535A/zh active Pending
- 2020-05-27 US US17/613,632 patent/US20230174658A1/en not_active Abandoned
- 2020-05-27 MA MA056027A patent/MA56027A/fr unknown
- 2020-05-27 KR KR1020217042271A patent/KR20220012918A/ko not_active Ceased
- 2020-05-27 BR BR112021023906A patent/BR112021023906A2/pt unknown
- 2020-05-27 SG SG11202112909SA patent/SG11202112909SA/en unknown
- 2020-05-27 MX MX2021014572A patent/MX2021014572A/es unknown
- 2020-05-27 WO PCT/IB2020/055023 patent/WO2020240434A1/en not_active Ceased
- 2020-05-27 JP JP2021570263A patent/JP7755999B2/ja active Active
-
2021
- 2021-11-22 IL IL288288A patent/IL288288A/en unknown
-
2025
- 2025-10-06 JP JP2025168433A patent/JP2026004525A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020240434A1 (en) | 2020-12-03 |
| CN113939535A (zh) | 2022-01-14 |
| JP2022534494A (ja) | 2022-08-01 |
| MX2021014572A (es) | 2022-03-17 |
| KR20220012918A (ko) | 2022-02-04 |
| IL288288A (en) | 2022-01-01 |
| BR112021023906A2 (pt) | 2022-01-25 |
| AU2020284706A1 (en) | 2021-12-16 |
| EP3976651A1 (en) | 2022-04-06 |
| JP2026004525A (ja) | 2026-01-14 |
| MA56027A (fr) | 2022-04-06 |
| US20230174658A1 (en) | 2023-06-08 |
| JP7755999B2 (ja) | 2025-10-17 |
| CA3142226A1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12377144B2 (en) | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | |
| IL272149A (en) | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors | |
| CN118453840A (zh) | 用于调节免疫应答的方法 | |
| CN113272326B (zh) | 治疗嗜中性病症的方法 | |
| JP2026004525A (ja) | 抗ｃｄ４０抗体の安全な投与を提供する方法 | |
| JP2016534090A (ja) | Ｃｄ３８アゴニストの医学的使用 | |
| CN117836318A (zh) | 用于降解靶蛋白的双特异性结合剂-配体融合物 | |
| TW202302640A (zh) | 抗tl1a抗體組合物及肺中之治療方法 | |
| EP3039039B1 (en) | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics | |
| TWI728400B (zh) | Cd226促效劑抗體 | |
| AU2022286960A1 (en) | Bcma targeting trispecific proteins and methods of use | |
| EP4556486A1 (en) | Trispecific antibody and use thereof | |
| CN119173276A (zh) | 用于治疗表达Trop-2的癌症的组合疗法 | |
| US20230140694A1 (en) | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies | |
| JP2020536923A (ja) | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 | |
| WO2023010095A1 (en) | Methods and compositions for treating cancer | |
| JP2021519338A (ja) | 測定された代謝産物レベルに基づいて治療剤の投与を決定する方法 | |
| US20190290635A1 (en) | Methods of treating brain cancer using agents that alter activity of a metabolic pathway | |
| HK40067213A (zh) | 提供抗cd40抗体的安全施用的方法 | |
| WO2016167809A1 (en) | Improved t-dm1 therapy | |
| US20220062390A1 (en) | Methods of treating cancer | |
| HK40109234A (zh) | 用於治疗癌症的方法和组合物 | |
| HK40062612A (en) | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics | |
| TW202541844A (zh) | Ｐｄ－１／ｉｌ－２ｒ雙特異性抗體融合蛋白及其用途和使用方法 | |
| CA2577883A1 (en) | Tnf-binding protein-1 in the treatment of psoriasis |